Abstract:Antibodies are capable of potently and specifically binding individual antigens and, in some cases, disrupting their functions. The key challenge in generating antibody-based inhibitors is the lack of fundamental information relating sequences of antibodies to their unique properties as inhibitors. We develop a pipeline, Antibody Sequence Analysis Pipeline using Statistical testing and Machine Learning (ASAP-SML), to identify features that distinguish one set of antibody sequences from antibody sequences in a reference set. The pipeline extracts feature fingerprints from sequences. The fingerprints represent germline, CDR canonical structure, isoelectric point and frequent positional motifs. Machine learning and statistical significance testing techniques are applied to antibody sequences and extracted feature fingerprints to identify distinguishing feature values and combinations thereof. To demonstrate how it works, we applied the pipeline on sets of antibody sequences known to bind or inhibit the activities of matrix metalloproteinases (MMPs), a family of zinc-dependent enzymes that promote cancer progression and undesired inflammation under pathological conditions, against reference datasets that do not bind or inhibit MMPs. ASAP-SML identifies features and combinations of feature values found in the MMP-targeting sets that are distinct from those in the reference sets.The availability of machine learning techniques and the exponential growth of sequencing data presents new opportunities to identify features that endow antibodies with the ability to disrupt the functions of biological targets. We have created a pipeline that uses statistical testing and machine learning techniques to determine features that are overrepresented in a specified set of antibody sequences in comparison to a reference set. The pipeline is referred to as Antibody Sequence Analysis Pipeline using Statistical testing and Machine Learning (ASAP-SML). We demonstrate the use of ASAP-SML by analyzing sets of antibodies that inhibit matrix metalloproteinases (MMPs) against reference sets. ASAP-SML performs within and across set similarity analysis. As in prior studies, our analysis of these datasets shows that features associated with the antibody heavy chain are more likely to differentiate MMP-targeting antibody sequences from reference antibody sequences. Further, ASAP-SML identifies several features in the MMP-targeting set that are distinct from the reference sets. Using design recommendation trees, ASAP-SML suggests combinations of features that can be included or excluded to augment the targeting set with additional candidate MMP-targeting antibody sequences.

Elucidating key determinants of engineered scFv antibody in MMP-9 binding using high throughput screening and machine learning

Soluble Expression and Characterization of a New scFv Directed to Human CD123

Explainable Machine Learning for Profiling the Immunological Synapse and Functional Characterization of Therapeutic Antibodies.

Production of a Ribosome-Displayed Mouse scFv Antibody Against CD133, Analysis of Its Molecular Docking, and Molecular Dynamic Simulations of Their Interactions

Machine learning optimization of candidate antibody yields highly diverse sub-nanomolar affinity antibody libraries

ASAP-SML: An antibody sequence analysis pipeline using statistical testing and machine learning

An integrated technology for quantitative wide mutational scanning of human antibody Fab libraries

Improved Soluble ScFv ELISA Screening Approach for Antibody Discovery Using Phage Display Technology

Multiplex Evolution of Antibody Fragments Utilizing a Yeast Surface Display Platform.

Molecular Modeling and Affinity Determination of Scfv Antibody: Proper Linker Peptide Enhances Its Activity

Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms

Structure-based engineering to restore high affinity binding of an isoform-selective anti-TGFβ1 antibody

Efficient construct of a large and functional scFv yeast display library derived from the ascites B cells of ovarian cancer patients by three-fragment transformation-associated recombination

Engineering Peptide Linkers for scFv Immunosensors

Engineering affinity of humanized ScFv targeting CD147 antibody: A combined approach of mCSM-AB2 and molecular dynamics simulations

Paratope mapping of tilvestamab, an anti-AXL function blocking antibody, using high-throughput bacterial expression of secreted scFv-ompY fusion proteins

Site-directed Mutations of Anti-Amantadine Scfv Antibody by Molecular Dynamics Simulation: Prediction and Validation

[Expression, structure prediction and functional analysis of murine single-chain fragment variable antibody against human cervical cancer].

MVSF-AB: Accurate antibody-antigen binding affinity prediction via multi-view sequence feature learning

AI/ML combined with next-generation sequencing of VHH immune repertoires enables the rapid identification of de novo humanized and sequence-optimized single domain antibodies: a prospective case study